PHAR - Pharming Group NV

PHAR - Pharming Group NV

https://www.pharming.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 1 week, 5 days ago • score: -0.04

Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. ( "Pharming" ) ( Euronext Amsterdam: PHARM/Nasdaq: PHAR ) announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025.

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference - Pharming ( NASDAQ:PHAR )

Benzinga • 1 week, 5 days ago • score: -0.03

Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. ( "Pharming" ) PHAR announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025.

Pharming Group to participate in August investor conference

GlobeNewswire • 1 month, 1 week ago • score: 0.05

Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. ( "Pharming" ) ( Euronext Amsterdam: PHARM/Nasdaq: PHAR ) announces that Pharming's management will participate in the following investor conference in the month of August: ...

Pharming Group to participate in August investor conference - Pharming ( NASDAQ:PHAR )

Benzinga • 1 month, 1 week ago • score: -0.03

Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. ( "Pharming" ) PHAR announces that Pharming's management will participate in the following investor conference in the month of August:

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.

52W High

$17.08

52W Low

$6.73

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.59

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

50.76

EV/EBITDA (<8 favorable)

34.84

EV/Revenue (<3 favorable)

3.03

P/S (TTM) (<3 favorable)

3.08

P/B (<3 favorable)

4.37

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

0.09%

Shares Outstanding

68,515,000

Float

670,712,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

339,836,000

Gross Profit (TTM)

303,509,000

EPS (TTM)

-0.14

Profit Margin (>10% good)

-0.02%

Operating Margin (TTM) (higher better)

0.03%

ROE (TTM) (>15% strong)

-0.04%

EPS YoY (Quarterly) (>10% good)

-0.62

Revenue YoY (Quarterly) (>8% good)

0.26

Momentum

Bearish momentum

Value

0.8638

Previous

0.8926

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025